Table 3.
Summary of Significant GM and KM Associations (allotype/phenotype) in Different IIM Clinical and Autoantibody Groups.*
| EA | AA | ||||
|---|---|---|---|---|---|
| Clinicopathologic Groups | Adult | Juvenile | Adult† | Juvenile | |
| PM | (allotype) | KM 1 | |||
| DM | (allotype) | GM 13 | GM 13 | ||
| (phenotype) | GM 3 23 5,13 | GM 3 23 5,13 | KM 1,1 | ||
| GM 1,3,17 5,13,21 | |||||
|
| |||||
| Myositis Autoantibody Groups | |||||
| IIM MSA: | |||||
| anti-Jo-1 (phenotype) | GM 3 23 | 5,13 | |||
| anti-PL-7 (allotype) | GM 3 | ||||
| anti-SRP (allotype) | GM 6 | ||||
| IIM MAA: | |||||
| anti-RNP (allotype) | GM 3 | ||||
| anti-Ro (phenotype) | KM 1,1 | ||||
*
Abbreviations: per Tables 1 - 2. Markers identified as protective factors are listed in italics. All clinical and autoantibody subgroups were examined for GM and KM associations and a blank notation in that column means no significant associations were found.
†
The GM 5 allotype was also identified as a risk factor for adult AA IIM patients.